NCT02572336 - A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPA | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

April 30, 2016

Conditions

Ischemic Stroke

Interventions

DRUG

THR-18

THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.

DRUG

Placebo

Placebo is a THR-18 lookalike, to be administered with tPA.

DRUG

Tissue Plasminogen Activator (tPA)

tPA is a thrombolytic agent. tPA is not an investigational drug.

Trial Locations (1)

Unknown

RECRUITING

Municipal Emergency Hospital, Chisinau